Despite promising preclinical results, the clinical benefits of cancer gene therapy have been modest heretofore. The main obstacle continues to be the level and persistence of gene delivery to sufficiently large areas of the tumor. One approach for overcoming this might entail extended local virus release. We studied the utility of silica gel monoliths for delivery of adenovirus to advanced orthotopic gastric and pancreatic cancer tumors. Initially, the biochemical properties of the silica-virus matrix were studied and nearly linear release as a function of time was detected. Virus stayed infective for weeks at +37 1C and months at +4 1C, which may facilitate storage and distribution. In vivo, extended release of functional replication deficient and also replication-competent, capsid-modified oncolytic viruses was seen. Treatment of mice with pancreatic cancer doubled their survival ( Po0.001). Also, silica gel-based delivery slowed the development of antiadenovirus antibodies.
Introduction
Gastric and pancreatic cancers are devastating diseases lacking curative treatments, when metastatic. Gastric cancer is the second most common cause of cancer deaths worldwide, with 934 000 cases yearly and a mortality of 75%. 1 A total of 232 000 new pancreatic cancer cases are detected yearly, and 98% of patients die of the disease. Treatment options for advanced pancreatic and gastric cancer include chemotherapy and radiation therapy, but they extend survival only marginally and often with side effects. 2, 3 Thus, the need for new treatment strategies is evident.
Oncolytic viruses including replication-competent adenoviruses are emerging as a promising tool for the treatment of cancer. [4] [5] [6] They have the unique property of tumor-dependent self-perpetuation, which allows effective local amplification of effect and subsequent intratumoral and systemic dissemination. Encouraging results have been obtained from extensive preclinical studies, and although clinical safety data have been excellent, efficacy has usually been modest. 4, 6, 7 Nevertheless, dozens of responses in early trials and the completed randomized trials indicate that the concept is valid and that the potential for efficacy exists. 4, [6] [7] [8] Importantly, preclinical and clinical works have identified some of the main obstacles to more emphatic results. Tumor transduction remains key to efficacy, and although capsid-modified oncolytic viruses have emerged for improving this aspect, intratumoral complexities including stromal barriers and necrotic areas remain problematic. 6, 7 In particular, given the suboptimal bioavailability of oncolytic viruses (most viruses end up in the liver), little virus remains long in the vicinity of the tumor after injection, regardless of route of administration. Therefore, an extended release device might be helpful.
Another crucial issue that limits readministration is induction of a neutralizing antibody response. [9] [10] [11] [12] [13] Thus, approaches that attenuate or postpone antibody formation might be useful for facilitating readministration. Although the tumor environment may be relatively immune privileged, peritumoral and systemic viral dissemination might be more effective if antibody induction is slower.
The possibility of immobilizing drugs and even cells into sol-gel polymers without the loss of biological activity has led to the development of drug delivery carriers. 14 The process is based on inorganic polymerization in conditions compatible with biologicals, allowing the association of mineral phases with organic materials. The material is biodegradable in vivo and is subsequently secreted into urine. 15 Biodegradation is the main mechanism controlling the release rate of large encapsulates in vitro and is flexibly adjustable to the desired degradation rate. 16 Combining anticancer agents into an implantable and degradable delivery matrix attempts to modify drug biodistribution, reduce drug toxicity and thus improve therapeutic efficacy. Advantages include higher local drug concentration, longer target exposure to the drug and spontaneous degradation of the implant.
The sol-gel formulation differs from common SiO 2 drug delivery formulations in one important detail; both the final formulation and the process itself are designed to contain substantial amounts of water. This ensures large pores in an aqueous environment, which can be a hospitable environment for viruses. For an implantable device, high water content can be problematic with regard to structural homogeneity as a function of time. However, storage of gel in small volumes of water rapidly saturates the SiO 2 content, which stops degradation. Theoretically, viruses might therefore remain encapsulated and infective for months. 17 Here, we sought to study these theoretical aspects in practise, in the context of silica gel-encapsulated adenoviruses.
Results

Silica dissolution and virus release in vitro
In vitro dissolution of silica gel without virus was found linear (R 2 ¼ 0.9381, Figure 1a ). Next, replicationdeficient adenovirus was imbedded in silica and degradation was studied over a longer time period (Figure 1b) . The amount of released virus was maximized for PCR conditions, because large volumes are needed to dissolve silica gel in in vitro systems, where there is no constant flow and renewal of liquids as in in vivo. When degrading the implant in Tris-HCl buffer, the amount of the virus released from the silica gel increased over time. Viral release kinetics were in accordance with silica gel degradation (Figure 1b) . However, a few days were required for the outer layer of the silica gel to dissolve, after which virus release was nearly linear. The lag time may indicate that the surface of the gel is slightly dryer than the matrix. A similar lag time has previously been reported in the context of large encapsulates such as proteins. 16 The protective properties of the outer layers of the silica gel were confirmed in another assay, where much more virus release was seen after degradation of 30% of the silica matrix, as opposed to naive silica gels (Supplementary Figure 1) . Linear virus liberation suggests that the release mechanism is dependent on silica dissolution, which is in accordance with earlier observations with proteins. 
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In vitro release and infectivity of silica-embedded virus Modification of the adenovirus capsid might theoretically affect release from silica matrix. Therefore, we embedded Ad5-D24RGD (capsid contains an integrin-binding RGD-4C moiety) in silica and studied the release of infectious particles. Again, release of infectious units as a function of time was linear (R 2 ¼ 0.927, Figure 1c ).
Stability of silica-embedded viruses in vitro
AdlacZ216 embedded in silica was still functional and capable of gene transfer after incubation for 229 days (ongoing at time of manuscript preparation) at +4 1C (Figure 1d ). The TCID 50 method was used to estimate the infectivity of the viruses encapsulated in the silica gels stored at 4 1C. On account of slow degradation in serumlike mediums, saturation of medium in vitro and lack of silica solvents not toxic to viruses, complete dissolution of the gels is not possible and therefore it is not possible to demonstrate the presence of the entire input functional dose. However, TCID 50 suggested the presence of infective viruses in the silica stored for up to 855 days at 4 1C ( Table 1) . Currently, adenoviruses are transported and stored at À80 1C, which is not practical at most hospitals. Therefore, the utilization of silica matrix might eventually facilitate the routine use of adenovirus-based medicines.
To test stability at 37 1C, LacZ-coding virus was imbedded in silica and incubated in phosphate-buffered saline (PBS) for up to 32 days, after which fibroblasts were added on silica gels (Figure 2a ). 5-Bromo-4-chloro-3-indolyl-D-galactopyranoside (X-gal) staining confirmed the presence of functional viruses in the gel for up to 28 days. After incubating the gel at 37 1C for 32 days, no functional virus was detected.
Silica biodegradation and release of functional virus in vivo
The in vivo biodegradation rate of sol-gel SiO 2 has been found about 8-10 fold slower than that in vitro. 15 To Gels containing replication-deficient adenovirus coding for LacZ were placed in a 24-well cell culture plate and incubated in PBS for the indicated number of days, after which HSF cells were added to the wells. Three days later, cells were stained with X-gal (green). Negative controls did not show staining (not shown). (b) Silica gel implants with adenovirus coding for LacZ were implanted subcutaneously in C57Bl mice. Positive control mice received the same amount of virus in the same area. As negative controls, mice receiving neither virus nor implant and mice with virus-free implant were analyzed (all were negative and thus one representative sample is shown). Histological samples from tissue surrounding the implant were collected at selected time points and stained with X-gal and counterstained with eosin (at 14 days) or with hematoxylin-eosin (other time points). Si ¼ silica implant; days ¼ after implantation of silica gel. (c) Release of virus from silica implants into orthotopic gastric tumors. Tumors were grown in SCID mice and treated with 7.6 Â 10 7 VP of oncolytic adenovirus Ad5/3-D24-TK-GFP either as an intraperitoneal injection (i.p.) or in a silica implant. Tumors were collected after 2, 5 and 8 days later and stained with a GFP-specific antibody (brown). GFP, green fluorescent protein; HSF, human skin fibroblast; PBS, phosphate-buffered saline; SCID, severe combined immunodeficiency; VP, viral particle.
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corroborate virus release in vivo, silica gel implants with LacZ-coding virus were implanted subcutaneously in mice ( Figure 2b ). As seen in vitro, increasing virus release and LacZ transfer was seen as a function of time. In comparison to needle injection, silica-imbedded virus seemed to result in more intense and wide-spread staining of tissues around the area of implantation, suggesting the utility of extended release. The blue signal becoming stronger after 7 and 14 days some distance away from the implant is seen reproducibly when virus is used in immune-competent mice, perhaps reflecting the clearance of virus-transduced cells by the immune system. In parallel to what is seen in clinical trials featuring intratumoral administration, direct injection resulted in patchy infection of mostly the needle tract. 18 The implant had resorbed completely by day 21.
Next, virus release was studied in orthotopic murine tumors, which may be superior over subcutaneous models, as they capture the effect of the tumor environment better. 19 Oncolytic and serotype 5/3 chimeric adenovirus coding for TK-GFP (Ad5/3-D24-TK-GFP) was released from silica and resulted in green fluorescent protein (GFP) expression in intraperitoneal gastric cancer tumors (Supplementary Figure 2) . GFP production of the virus is linked to replication and therefore GFP expression confirms that (a) 5/3 chimeric virus is stable in and releases from the implant, (b) 5/3 chimeric virus released from the implant can transduce intraperitoneal tumors in vivo and (c) oncolytic virus released from the implant retains the capacity for replication in tumor cells.
However, fluorescent imaging of GFP is not very sensitive in this setting and rapid oncolysis of infected cells further reduces sensitivity. Therefore, we also stained for GFP (Figure 2c) . A strong GFP signal was seen in needle-injected mice on days 2 and 5, after which the signal faded by day 8, because of oncolytic death of infected cells. In silica-treated mice, the GFP signal was weaker on days 2 and 5, and grew stronger by day 8, suggesting a slower release from the silica implant. Further studies may be needed for the investigation of later time points. Mock mice implanted with silica without virus did not show GFP staining.
To study gene delivery to normal and tumor tissues in an even more aggressive model, luciferase-expressing replication-deficient capsid-modified Ad5/3luc1 was embedded in silica and implanted into mice with advanced and disseminated pancreatic cancer. For comparison, the same amount of virus was injected directly intraperitoneally ( Figure 3 ). As seen with the gastric cancer model, direct intraperitoneal injection resulted in high early gene expression, whereas silica implant released virus slower. At 2 weeks, levels were equivalent suggesting that much of the virus packaged in silica had been released. Further, luciferase readings in the silica group were within 1 log of readings obtained on day 2 with needle-injected virus, suggesting that most of the virus implanted in the silica gel remained functional and was released as expected.
To study tumor transduction and persistence of virus replication, an oncolytic capsid-modified adenovirus (Ad5/3D24hCGb) coding for the b subunit of human chorionic gonadotropin (hCGb) was used ( Figures  4a-c) . 20 Following intraperitoneal virus injection or silica gel implantation, tumors and livers were harvested at selected time points to quantify the amount of infective viruses (Figures 4a-b) . In needle-injected mice, the highest amount of virus in tumor and liver was seen on day 2, whereas in silica-implanted mice, the amount of virus increased continuously for 2 weeks.
Replication of Ad5/3D24hCGb is tightly linked to secretion of hCGb, which can be measured from blood. 20 In intraperitoneally injected mice, the highest virus replication was seen on day 2, after which the replication declined (Figure 4c ). We speculate that the most accessible areas of the tumors were infected first and then lysed in the first round of virus replication. The lower subsequent levels of hCGb production reflect penetration deeper into the tumor and slower replication due to a suboptimal environment caused by necrosis and debris caused by the initial damage. In mice receiving virus embedded in silica, hCGb increased steadily up to day 10 and remained higher also thereafter. The overall peak value reached with the silica treatment was 5.5-fold lower compared with intraperitoneal injection. Theoretically, slower virus release might be beneficial for tumor penetration, if it helps avoiding high initial damage to the surface and perivascular regions of the tumors, which may compromise intratumoral dissemination and reinfection. Thus, silica-based delivery may help in overcoming aforementioned intratumoral complexities. This, however, remains speculative and remains to be studied in future experiments. Further, as high viral peaks can result in high cytokine release, which can cause harmful and even dangerous immune cascades, a lower peak without reduction in the area under the curve might be useful with regard to safety. 21 
Antitumor efficacy and antibody response
To investigate the antitumor efficacy of oncolytic adenovirus embedded in silica, advanced orthotopic pancreatic tumors were allowed to develop and mice were implanted with silica gels with or without oncolytic adenovirus Ad5/3-D24 (Figure 4d ). Virus embedded in silica improved the median survival of mice from 57 to 91 days (60% increase, Po0.001).
In the experiments reported here, the dose of virus injected directly or in silica was the same. Therefore, the antibody response might be expected to be identical. On the other hand, antibody induction might be slower considering that the matrix protects most of the virus from immune cells until release upon degradation. To evaluate this, serum was collected from mice that had received an adenoviral silica implant or the same dose of virus alone (Figure 4e ). On day 7, more antibodies could be detected in the virus injection group (Po0.001). However, a week later (day 14), due to effective virus release from silica, antibodies in silica-implanted mice had reached the same level as seen in virus alone-treated mice.
Discussion
We found that eight different serotype 5-based or capsidmodified adenoviruses, both replication deficient and competent, could be imbedded in silica gel. Release of virus was linear in vitro and in vivo, suggesting that degradation of the matrix follows the expected kinetics and that virus release occurs in conjunction with degradation and not through pores present in the gel. Infectivity of the virus was sustained for at least 855 days at +4 1C, which may have many benefits with regard to the distribution and storage of adenovirus-based drugs, which currently need to be stored at À80 1C. Importantly, slower release kinetics resulted in extended presence of virus in orthotopic murine models of cancer. Figures 3 and 4 show most tissues featuring higher transduction/viral content at early time points with the intraperitoneally given virus, whereas higher transduction/viral content is seen at late time points with silicamediated delivery. The only exception is the liver, where high viral content was seen throughout following silica- 9 VP of Ad5/3-D24 in silica implants. Control mice were treated with silica implants without virus. Mice were followed for survival and the results were analyzed with the Kaplan-Meier method. (***Po0.001). (e) Antibody formation against adenovirus delivered within or without silica. Silica implants containing adenovirus were implanted subcutaneously to immune-competent C57Bl mice. The positive control group received the same amount of virus without silica subcutaneously. The negative control groups were treated with either silica implants alone or with subcutaneous medium injection without virus (all negative and thus only one negative group is shown). Serum was collected at 3, 7, 14 and 21 days following the treatment and antiadenoviral antibodies were measured with EIA. Error bars indicate s.e. (***Po0.001 versus virus in silica). EIA, enzyme immunoassay; hCGb, human chorionic gonadotropin; SCID, severe combined immunodeficiency; VP, viral particle. (Figure 4b ). We do not fully understand this, but one possibility is that it reflects partly silicated virus stuck in liver sinusoids. Free virus would rapidly enter cells of the liver, and thus not be detectable with TCID 50 assay, but virus stuck in sinusoids would be readily detected. Also, as mouse cells do not allow effective replication of human adenovirus, these results probably do not correlate with transduction of liver cells. Instead, they may reflect the opposite; virus present in the liver but outside the cells. If indeed high TCID 50 values reflect virus stuck in sinusoids (instead in cells of the liver), this might in fact reflect lower toxicity, because liver toxicity presumably only arises from cells that have taken up or been infected with virus. Alternatively, higher liver virus content could reflect highly potent virus replication (and subsequent vascular-mediated transduction of the liver) following slower release from the implant. It is unlikely that the threshold effect of Kupffer cells has a function here as doses used are well below the capacity of Kupffer cell uptake, which is between 1 and 2 Â 10 10 viral particles (VPs). 22 Virus imbedded in silica had prominent antitumor activity in an orthotopic murine model of pancreatic cancer. Future plans include studying the therapeutic effect of silica-embedded virus compared with other administration methods. Also, additional experiments are needed to understand the interactions of adenovirus with silica in vivo, post-release. Further experiments are also needed to analyze if slower release from implants is a positive attribute also in other diseases and gene delivery settings. Improvements in the technology (such as injectable silica formulations) may be useful for optimal therapeutic efficacy and our plan is to develop the technology further before analyzing efficacy in optimally controlled rigorous survival experiments. A higher water content in the silica allows faster release whereas for some applications, slower release may be beneficial. It will be interesting to study the effect of the speed of release in various disease settings.
Silicated adenovirus
Antibody formation was slower when virus was delivered in silica, which might be useful in the context of efficacy in the face of a mounting antibody response. To our knowledge, this is the first report of viral delivery from a silica-based delivery system in vivo. Although we did not detect any silica-related side effects in our studies, further work is required to analyze the safety and efficacy of the approach in animal models, before possible clinical testing.
Materials and methods
Cells
A549 human lung adenocarcinoma cells, 293 embryonal kidney cells and Panc-1 pancreatic cancer cells are from American Type Culture Collection (Borås, Sweden). Primary adult human skin fibroblasts (HSFs) were established from a skin punch biopsy obtained from the arm of a healthy male volunteer (age 27) after informed consent. Intestinal type gastric cancer cell line MKN-28 was a kind gift from Dr Hiroshi Yokozaki (Kobe University). All lines were cultured as recommended.
Adenoviruses
Firefly-luciferase-coding Ad5/3luc1, 23 Escherichia coli LacZ gene-coding RadlacZ, 24 transgene-less RAd66 24 and nuclear targeted LacZ-coding adenovirus AdlacZ216 25 are replication deficient. Replication competent viruses Ad5/3-D24, 12 hCGb (a biologically inactive secretable marker peptide)-coding Ad5/3D24hCGb 20 and TK-GFPcoding Ad5/3-D24-TK-GFP 26 are targeted to the adenovirus serotype 3 receptor, which is expressed to high degree on many tumor types. 19, 20, 23 Ad5-D24RGD 27 is targeted to avb-class integrins also highly expressed by many tumors. Replication competent and deficient viruses were propagated on A549 and 293 cells, respectively, and purified on cesium chloride gradients. VP concentration was determined at 260 nm, infectious particles (plaque-forming units (PFU)) were measured with standard plaque assay. These and other quality analysis and control measures were implemented as reported. 26 
Silica gels
Silica gels were prepared at room temperature from tetraethoxysilane (TEOS, Aldrich, Milwaukee, WI, USA) and water. Nitric (2 M) or acetic acid was used as a catalyst. All liquids were sterile filtered through a 0.22 mm filter. Initially, a silica sol was prepared by letting TEOS react with water (hydrolysis followed by polycondensation) using 50 ml of nitric acid as a catalyst. The mixture was vigorously stirred for 90 min and the resulting sol was cooled down to +4 1C. Before virus addition, pH was adjusted to 6.6 by adding 1 M NaOH, which resulted in a total sol volume of 10-11 ml. The virus stock (100-200 ml) was added while vigorously mixing. Virus content of the sol was typically 6 Â 10 7 PFU ml
À1
(concentrations between 10 7 and 10 9 PFU ml À1 tested). While stirring, 200 or 400 ml sol aliquots were injected into cylindrical moulds with a diameter of 7 or 11 mm, respectively. The sols were stored at +4 1C in a desiccator with drying agent (Zeochem, Rubingel, Uetikon, Switzerland). The sols turned into gels within 5-10 min, after which the gels were allowed to age for 20-24 h. Water content of the resulting silica gel was 90 ± 3 w% (determined with thermogravimetric analysis by Mettler TGA 851e and Perkin Elmer TGA7).
Dissolution and in vitro virus release
Silica degradation was studied by dissolving a 400 ml gel in 250 ml of 0.05 M Tris-Cl buffer (pH 7.4) at +37 1C (Sigma, St Louis, MO, USA). The released Si was quantified with a UV-VIS spectrophotometer (Shimadzu UV-1601) utilizing the molybdenum blue method based on the reduction of 1-amino-2-naphtol-4-sulfonic acid. The amount of released SiO 2 (n ¼ 3) was compared with the SiO 2 content of the implant, extrapolated by linear regression and expressed as w%. Virus release from the degrading gel (n ¼ 4) was studied by dissolving the gel in 250 ml of Tris-Cl buffer for 9 days. The buffer was changed every third day to allow maximal degradation. Therefore, the new data point values are added to the previous ones. Adenoviral genomes were measured with quantitative PCR. 28 In vitro release and infectivity of silica-embedded virus Gels (400 ml) containing 7.6 Â 10 7 VP of Ad5-D24RGD (n ¼ 12) or no virus (n ¼ 6) were studied for in vitro release and infectivity. Dissolution tests were performed 26 Virus stability in vitro Gels with 1.5 Â 10 7 VP of AdlacZ216 were incubated at +4 1C in buffered water for 229 days, after which they were incubated in PBS at +37 1C in 5% CO 2 for 3 days and transferred onto HSF cells for 3 days to visualize viable virus (Figure 1d) . After 3 days, cells were fixed with glutaraldehyde and stained with X-gal (Promega, Madison, WI, USA). Gels with virus but without cells and gels with cells but no virus served as negative controls. To investigate viral release from the gels, 30 w% of monolith matrix was allowed to degrade in PBS. The remainder was cultured with 5 Â 10 4 HSF cells on a 24-well plate, and transfection was visualized by X-gal staining. For comparison, an intact gel without preceding degradation was cultured on HSF cells.
The TCID 50 method was used to further confirm the infectivity of the viruses in the silica gels stored at +4 1C. The implants were stored in a small volume of water solution that is saturated with respect to the dissolution product of silica (that is, silica does not dissolve and the viruses are not released). After storage (for 7, 470 and 855 days), the implants were transferred from the storage solution to PBS for dissolution to release the encapsulated viruses. Rapid total dissolution of the silica gels (designed for in vivo dissolution) is not possible in vitro without massive loss of functional virus. Dissolution in medium suitable for viruses is slow and carried out at +37 1C, 29, 30 also leading to the loss of functional virus. Therefore, it is not possible to confirm the presence of all input functional viruses in the silica gel. Total release takes time and large dissolution medium volume is needed in a non-flowing system. Dissolution was carried out at +37 1C. Samples were taken at four different time points for the TCID 50 test. Implant was still clearly visible after 312 h of dissolution (13 days). Hence, the implants were only partly dissolved and consequently, also the virus release was partial. The initial amount of virus in gels was 1-6 Â 10 8 PFU. For gels stored for 855 days, original PFU titer was estimated from VP titer.
Animals
Subcutaneous silica treatments were carried out with C57Bl mice (Taconic, Ejby, Denmark). For intraperitoneal studies, female Fox Chase severe combined immunodeficiency mice (Taconic) were used. Mice were purchased at 4-5 weeks of age and quarantined for 2 weeks before the study. Mice were kept under pathogen-free conditions according to European Union guidelines. Animal experiments were approved by the Experimental Animal Committees of the Universities of Helsinki and Turku and the Provincial Government of Southern Finland.
In vivo virus release from subcutaneous silica implants
Silica implants (200 ml) containing 8.8 Â 10 6 PFU of AdlacZ216 were implanted subcutaneously under the dorsal skin of anesthesized C57Bl mice. Six-mm long full-thickness wounds were sealed with sterile plasters.
Positive control mice received the same amount of virus injected in the same area. Mice receiving neither virus nor implant and mice with virus-free silica implants served as negative controls. Histological samples and blood were collected from two animals at each time point. Histological samples were rinsed with 2 mM MgCl 2 -PBS and fixed with 0.5% glutaraldehyde for 3 h at +4 1C. Tissues were rinsed overnight with 2 mM MgCl 2 -PBS and stained for b-galactosidase activity with X-gal. Sections were further stained with hematoxylineosin (Sigma) or eosin alone (Sigma). Antiadenoviral antibodies were measured from the serum with enzyme immunoassay at the Department of Virology, University of Turku.
In vivo virus release from intraperitoneal silica implants
Orthotopic gastric cancer was established by intraperitoneal injection of MKN-28 cells (5 Â 10 6 ) into severe combined immunodeficiency mice. 19 Sixteen days later, mice were randomized into three treatment groups: 7.6 Â 10 7 VP of Ad5/3-D24-TK-GFP was either injected intraperitoneally in 400 ml Eagle's Minimum Essential Medium (Sigma) (n ¼ 6) or delivered in a 400 ml silica implant (n ¼ 6). Implants were surgically implanted through a 7 mm incision of the skin and abdomen. After implantation, the wound was sealed with three sutures. Control mice (n ¼ 3) received a silica implant with no virus. After 2, 5 and 8 days, mice were killed and tumors were processed as 6 mm cryosections. Histological staining with rabbit polyclonal antibody against GFP (Abcam, Cambridge, UK) and with DakoCytomation LSAB2 System-HRP (Carpinteria, Carpinteria, CA, USA) was performed according to the manufacturer's protocols.
A pancreatic cancer orthotopic model was developed by intraperitoneal injection of 7 Â 10 6 Panc-1 cells into severe combined immunodeficiency mice. After 22 days, mice received 5 Â 10 8 VP Ad5/3D24hCGb or Ad5/3luc1 either in a 100 ml silica implant (n ¼ 5) or in 100 ml Eagle's Minimum Essential Medium (n ¼ 5). Untreated mice received the equivalent amount of silica (n ¼ 3) or Eagle's Minimum Essential Medium (n ¼ 3) with no virus. Organs were snap-frozen using dry ice, ground and freeze-thawed thrice, lysed with 300 ml cell culture lysis buffer (Promega) and quantified for luciferase (Luciferase Assay System, Promega). Protein concentration was determined by using a detergent-compatible protein assay kit (Bio-Rad, Hercules, CA, USA). Serum samples for hCGb analysis were collected from the tail vein. hCGb concentration was quantified with a timeresolved immunofluorometric assay based on free hCGbspecific monoclonal antibodies with a 2 pmol l À1 cutoff. 31 Background level in non-treated mock mice was 37.2 pmol l À1 after 78 days of tumor growth, which was subtracted from values obtained from virus-treated mice. For virus replication assay, one mouse/time point was killed for harvesting the tumor and the liver. Organs were snap-frozen on dry ice, ground, freeze-thawed thrice and diluted into 500 ml Dulbecco's Modified Eagle's Medium, after which standard TCID 50 test was performed. 26 
In vivo survival
The Panc-1 pancreatic cancer model was used. Mice were treated with 1 Â 10 9 VP of Ad5/3-D24 in a 300 ml silica implant (n ¼ 7). Control mice received the same amount of silica without virus (n ¼ 4).
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Statistical analysis
Two-tailed Student's t-test was used to compare the differences between treatment groups. Survival was analyzed according to Kaplan-Meier with SPSS 11.5 for Windows.
